Catalyst Pharmaceuticals

Catalyst Pharmaceutical Partners, Inc.
TypeSubsidiary
Nasdaq: CPRX
IndustryBiotechnology
FounderPatrick J. McEnany
Headquarters
Key peoplePatrick J. McEnany (chairman
Richard Daly (CEO and Board member)
ProductsFIRDAPSE® (amifampridine) Tablets 10 mg (commercialized 2019)
AGAMREE® (vamorolone) Oral suspension 40mg/ ml
FYCOMPA® (perampanel) CIII
Increase US$ 86.8 million (2023)
Total assetsUS$ 700 million (2023)
Total equityUS$ 302.9 million (2023)
Number of employees
176
ParentAngelini Pharma
Websitewww.catalystpharma.com
Footnotes

Catalyst Pharmaceuticals, Inc. is a biopharmaceutical company based in Coral Gables, Florida, United States. The company develops medicines for rare diseases, including the phosphate salt of amifampridine for the treatment of Lambert–Eaton myasthenic syndrome (LEMS). The drug is referred to under the trade name Firdapse, which was approved by the FDA for approved use in children 6 years and older with LEMS in addition to the prior approval for use in adults with LEMS on November 28, 2018. Firdapse commercially launched in January 2019.